When will Lasmiditan Succinate Tablet be back in stock?

The FDA lists an estimated recovery date per manufacturer where known; check the FDA note column below. National FDA records do not reflect your local pharmacy's shelf.

How do I get an alert when Lasmiditan Succinate Tablet changes?

Sign up for a change-only email alert on this page, or subscribe to the RSS or JSON feed. You are notified only when the FDA record changes.

← all medications

Lasmiditan Succinate Tablet

Brand names: Reyvow

Category: Neurology

Not specified 6

FDA status: To Be Discontinued · Last FDA update: Nov 3, 2025 · First posted: Nov 3, 2025 · 1 manufacturers, 6 listed presentations

As of Nov 3, 2025, the FDA lists Lasmiditan Succinate Tablet as being discontinued. Of 6 manufacturer presentations, 6 Not specified.

Ask your pharmacist: which of the 1 manufacturers below can they order right now, and whether a different strength or form of Lasmiditan Succinate Tablet is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.

Presentation & package NDC	Manufacturer	Availability	FDA note
Reyvow, Tablet, 50 mg (NDC 0002-4312-62) NDC 0002-4312-62	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Reyvow, Tablet, 50 mg (NDC 0002-4312-61) NDC 0002-4312-61	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Reyvow, Tablet, 50 mg (NDC 0002-4312-08) NDC 0002-4312-08	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Reyvow, Tablet, 100 mg (NDC 0002-4491-08) NDC 0002-4491-08	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Reyvow, Tablet, 100 mg (NDC 0002-4491-61) NDC 0002-4491-61	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Reyvow, Tablet, 100 mg (NDC 0002-4491-62) NDC 0002-4491-62	Eli Lilly and Co.	Not specified	A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.

Related medications in shortage

Other Neurology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Lasmiditan Succinate Tablet (FDA data as of Nov 3, 2025). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Lasmiditan Succinate Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Lasmiditan Succinate Tablet.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/lasmiditan-succinate-tablet.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).